5-甲氧基-6-硝基吡啶甲酸甲酯 | 390816-44-1

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-甲氧基-6-硝基吡啶甲酸甲酯
• 英文名称: 5-methoxy-6-nitro-pyridine-2-carboxylic acid methyl ester
• 英文别名: Methyl 5-methoxy-6-nitropicolinate；methyl 5-methoxy-6-nitropyridine-2-carboxylate
• CAS: 390816-44-1
• 化学式: C₈H₈N₂O₅
• 分子量: 212.162
• InChiKey: OCQAYEZVBSVDLF-UHFFFAOYSA-N

物化性质

• 沸点：
  380.9±37.0 °C(Predicted)
• 密度：
  1.356±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  94.2
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  5-甲氧基-6-硝基吡啶甲酸甲酯 在 铁粉 、 溶剂黄146 、 水 、 碳酸氢钠 作用下， 反应 0.5h， 生成 6-amino-5-methoxy-pyridine-2-carboxylic acid methyl ester
  参考文献：
  名称：

  WO2008/125111

  摘要：

  公开号：
• 作为产物：
  描述：

  5-甲氧基-6-硝基甲酸吡啶 、 碘甲烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 5-甲氧基-6-硝基吡啶甲酸甲酯
  参考文献：
  名称：

  WO2008/125111

  摘要：

  公开号：

文献信息

• Viral polymerase inhibitors
  申请人：Boehringer Ingelheim (Canada) Ltd.

  公开号：US20030236251A1

  公开（公告）日：2003-12-25

  An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: 1 wherein R 1 is selected from: H, haloalkyl, (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 3-7 )cycloalkyl, (C 2-6 )alkynyl, (C 5-7 )cycloalkenyl, 6 or 10-membered aryl, Het all optionally substituted; R 2 is selected from (C 1-6 )alkyl, (C 3-7 )cycloalkyl, (C 6-10 )bicycloalkyl, 6- or 10-membered aryl, or Het all optionally substituted; B is N or CR 5 , wherein R 5 is H, halogen, haloalkyl, (C 1-6 )alkyl, (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl; X is N or CR 5 ; D is N or CR 5 ; each of Y 1 and Y 2 is independently O or S; Z is O, N, or NR z wherein R z is H, (C 1-6 )alkyl, (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl; R 3 and R 4 are each independently H, (C 1-6 )alkyl, first (C 3-7 )cycloalkyl or 6- or 10-membered aryl, Het (C 1-6 )alkyl-6- or 10-membered aryl, (C 1-6 )alkyl-Het; or each R 3 and R 4 are independently covalently bonded together to form second (C 3-7 )cycloalkyl, or heterocycle, all optionally substituted; or when Z is N, either R 3 or R 4 are independently covalently bonded thereto to form a nitrogen-containing heterocycle; R 7 is H, (C 1-6 alkyl), (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl; or R 7 is covalently bonded to either of R 3 or R 4 to form a heterocycle; A is (C 1-6 ) alkyl-CONHR 8 wherein R 8 is-6- or 10-membered aryl, or Het; or A is a 6- or 10-membered aryl, or Het said aryl or Het being optionally substituted; or a salt or a derivative thereof; such compounds being potent inhibitors of HCV NS5B polymerase.

  公式I所代表的化合物的异构体、对映体、非对映异构体或互变异构体，其中R1选自：H、卤代烷基、(C1-6)烷基、(C2-6)烯基、(C3-7)环烷基、(C2-6)炔基、(C5-7)环烯基、6或10元芳基、Het均可选择性地取代；R2选自(C1-6)烷基、(C3-7)环烷基、(C6-10)双环烷基、6-或10元芳基、或Het均可选择性地取代；B为N或CR5，其中R5为H、卤素、卤代烷基、(C1-6)烷基、(C3-7)环烷基或(C1-6)烷基-(C3-7)环烷基；X为N或CR5；D为N或CR5；Y1和Y2中的每一个独立地为O或S；Z为O、N或NRz，其中Rz为H、(C1-6)烷基、(C3-7)环烷基或(C1-6)烷基-(C3-7)环烷基；R3和R4各自独立地为H、(C1-6)烷基、第一(C3-7)环烷基或6-或10元芳基、Het(C1-6)烷基-6-或10元芳基、(C1-6)烷基-Het；或每个R3和R4独立地共价结合在一起形成第二(C3-7)环烷基，或杂环，均可选择性地取代；或当Z为N时，R3或R4中的任一者独立地与之共价结合形成含氮杂环；R7为H、(C1-6烷基)、(C3-7)环烷基或(C1-6)烷基-(C3-7)环烷基；或R7与R3或R4中的任一者共价结合形成杂环；A为(C1-6)烷基-CONHR8，其中R8为6-或10元芳基，或Het；或A为6-或10元芳基，或Het所述芳基或Het可选择性地取代；或其盐或衍生物；这类化合物是HCV NS5B聚合酶的有效抑制剂。
• TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES
  申请人：Felding Jakob

  公开号：US20100113442A1

  公开（公告）日：2010-05-06

  The present invention relates to a compound according to formula (I), wherein X and Y are either C and N or N and C; Z is CH 2 , CH 2 —CH 2 , CH 2 —NH, or NH; R 1 is halogen, or R 1 is alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, cycloalkyl, alkoxycarbonyl, aryl, all of which are optionally substituted; R 2 is hydrogen, or R 2 is alkyl, cycloalkyl, alkoxy, heterocycloalkyl, aryl, heteroaryl, alkoxycarbonyl, aminocarbonyl, amino, all of which are optionally substituted; A is aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl or heterocycloalkenyl, all of which are optionally substituted; and pharmaceutically acceptable salts, hydrates, or solvates hereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments, in particular for the treatment of dermal diseases.

  本发明涉及一种化合物，其化学式为（I），其中X和Y分别为C和N或N和C；Z为CH2，CH2-CH2，CH2-NH或NH；R1为卤素，或R1为烷基，烯基，炔基，卤代烷基，烷氧基，环烷基，烷氧羰基，芳基，所有这些均可选择性地被取代；R2为氢，或R2为烷基，环烷基，烷氧基，杂环烷基，芳基，杂芳基，烷氧羰基，氨基羰基，氨基，所有这些均可选择性地被取代；A为芳基，环烷基，环烯基，杂芳基，杂环烷基或杂环烯基，所有这些均可选择性地被取代；以及其药学上可接受的盐，水合物或溶剂化物。本发明进一步涉及所述化合物在治疗中的应用，包括含有该化合物的制药组合物，使用该化合物治疗疾病的方法，例如皮肤疾病，并且涉及使用该化合物制造药物，特别是用于治疗皮肤疾病。
• Discovery and optimization of antibacterial AccC inhibitors
  作者：Cliff C. Cheng、Gerald W. Shipps、Zhiwei Yang、Binyuan Sun、Noriyuki Kawahata、Kyle A. Soucy、Aileen Soriano、Peter Orth、Li Xiao、Paul Mann、Todd Black

  DOI：10.1016/j.bmcl.2009.10.057

  日期：2009.12

  The biotin carboxylase (AccC) is part of the multi-component bacterial acetyl coenzyme-A carboxylase (ACCase) and is essential for pathogen survival. We describe herein the affinity optimization of an initial hit to give 2-(2-chlorobenzylamino)-1-(cyclohexylmethyl)-1H-benzo[d]imidazole-5-carboxamide (1), which was identified using our proprietary Automated Ligand Identification System (ALIS).(1) The X-ray co-crystal structure of 1 was solved and revealed several key interactions and opportunities for further optimization in the ATP site of AccC. Structure Based Drug Design (SBDD) and parallel synthetic approaches resulted in a novel series of AccC inhibitors, exemplified by (R)-2-(2-chlorobenzylamino)-1-(2,3-dihydro-1H-inden-1-yl)-1H-imidazo[4,5-b]pyridine-5-carboxamide (40). This compound is a potent and selective inhibitor of bacterial AccC with an IC(50) of 20 nM and a MIC of 0.8 mu g/mL against a sensitized strain of Escherichia coli (HS294 E. coli). (C) 2009 Elsevier Ltd. All rights reserved.
• VIRAL POLYMERASE INHIBITORS
  申请人：BOEHRINGER INGELHEIM (CANADA) LTD.

  公开号：EP1301487A2

  公开（公告）日：2003-04-16
• US6448281B1
  申请人：——

  公开号：US6448281B1

  公开（公告）日：2002-09-10